Literature DB >> 12469960

Management of irritable bowel syndrome.

Anthony J Viera1, Steve Hoag, Joseph Shaughnessy.   

Abstract

Irritable bowel syndrome is the most common functional disorder of the gastrointestinal tract and is frequently treated by family physicians. Despite patients' worries about the symptoms of irritable bowel syndrome, it is a benign condition. The diagnosis should be made using standard criteria after red flags that may signify organic disease have been ruled out. An effective physician-patient relationship is vital to successful management. Episodes of diarrhea are best managed with loperamide, while constipation often will respond to fiber supplements. Antispasmodics or anticholinergic agents may help relieve the abdominal pain of irritable bowel syndrome. Refractory cases are often treated with tricyclic antidepressants. Newer agents such as tegaserod and ondansetron target neurotransmitter receptors in the gastrointestinal tract Some forms of psychologic treatment may be helpful, and gastroenterology consultation is occasionally needed to reassure the patient. Comorbid conditions such as depression or anxiety should be investigated and treated.

Entities:  

Mesh:

Year:  2002        PMID: 12469960

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  4 in total

Review 1.  Irritable bowel syndrome.

Authors:  William E Cayley
Journal:  BMJ       Date:  2005-03-19

2.  Protective effect of Radix Acanthopanacis Senticosi capsule on colon of rat depression model.

Authors:  Gao-Hua Wang; Hai-Yan Dong; Wei-Guo Dong; Xiao-Ping Wang; He-Sheng Luo; Jie-Ping Yu
Journal:  World J Gastroenterol       Date:  2005-03-07       Impact factor: 5.742

Review 3.  Potential Causes and Present Pharmacotherapy of Irritable Bowel Syndrome: An Overview.

Authors:  Theodor Bokic; Martin Storr; Rudolf Schicho
Journal:  Pharmacology       Date:  2015-07-01       Impact factor: 2.547

4.  IBS Patients' Treatment Expectancy and Motivation Impacts Quality of the Therapeutic Alliance With Provider: Results of the IBS Outcome Study.

Authors:  Jeffrey M Lackner; Brian M Quigley; Christopher D Radziwon; Alison M Vargovich
Journal:  J Clin Gastroenterol       Date:  2021 May-Jun 01       Impact factor: 3.174

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.